Severe Hypophosphatemia After Ferric Carboxymaltose Infusion: A Case Report

Ferric carboxymaltose (FCM) allows for rapid and total correction of iron deficiency with a lower risk of hypersensitivity reactions compared to other IV iron preparations. However, FCM is associated with potentially serious adverse events, including hypophosphatemia, following the infusion. The mec...

Full description

Saved in:
Bibliographic Details
Published in:Hospital pharmacy (Philadelphia) 2024-10, Vol.59 (5), p.532-535
Main Authors: Arranz-Pasqual, N., Torrent-Rodríguez, A., Miana-Mena, M.T., López-Suñé, E., Corominas-García, N., Blanco, I., Soy-Muner, D.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ferric carboxymaltose (FCM) allows for rapid and total correction of iron deficiency with a lower risk of hypersensitivity reactions compared to other IV iron preparations. However, FCM is associated with potentially serious adverse events, including hypophosphatemia, following the infusion. The mechanism behind FCM-induced hypophosphatemia is not well understood, but pre-existing risk factors can increase the likelihood of severe and persistent hypophosphatemia. We report a clinical case of a male patient who developed severe hypophosphatemia (1.0 mg/dL) after administration of FCM for the treatment of post-cardiotomy normocytic anemia. He required hospital admission and 16 weeks of phosphorous supplementation.
ISSN:0018-5787
1945-1253
DOI:10.1177/00185787241242756